

Edgar Filing: SCHERING PLOUGH CORP - Form 8-K

SCHERING PLOUGH CORP  
Form 8-K  
July 26, 2004

SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K  
CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934

JULY 23, 2004  
Date of Report (Date of Earliest Event Reported)

SCHERING-PLOUGH CORPORATION  
(Exact name of registrant as specified in its charter)

NEW JERSEY  
(State or other jurisdiction  
of incorporation)

1-6571  
(Commission File Number)

22-1918501  
(IRS Employer  
Identification Number)

2000 GALLOPING HILL ROAD  
KENILWORTH, NJ 07033  
(Address of principal executive offices, including Zip Code)

(908) 298-4000  
(Registrant's telephone number, including area code)

ITEM 5. OTHER EVENTS AND REGULATION FD DISCLOSURE

FDA Approves VYTORIN

On Friday, July 23, 2004, the Merck/Schering Plough Pharmaceuticals joint venture announced that the U.S. Food and Drug Administration has approved VYTORIN(TM) (ezetimibe/simvastatin) for the treatment of high LDL cholesterol (LDL-C) in patients with primary hypercholesterolemia or mixed hyperlipidemia as adjunctive therapy to diet when diet alone is not enough. VYTORIN is the first and only product to deliver LDL cholesterol reduction through dual inhibition of the two sources of cholesterol in one tablet. The press release is attached as Exhibit 99.1 to this 8-K.

As noted in the Management's Discussion and Analysis of Financial Condition and Results of Operations section of Schering-Plough's first quarter

## Edgar Filing: SCHERING PLOUGH CORP - Form 8-K

2004 10-Q, the successful launch and commercial success of VYTORIN is important to Schering-Plough.

### ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS

(c) Exhibits. The following exhibit is filed with this 8-K:

99.1 Press Release issued by Merck/Schering-Plough Pharmaceuticals on July 23, 2004 titled "FDA Approves VYTORIN(TM) (ezetimibe/simvastatin), the First and Only Product to Deliver Powerful LDL Cholesterol Reduction Through Dual Inhibition of the Two Sources of Cholesterol in One Tablet"

### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Schering-Plough Corporation

By: /s/Douglas J. Gingerella  
Douglas J. Gingerella  
Vice President and Controller

Date: July 26, 2004

2

### Exhibit Index

The following exhibit is filed with this 8-K:

99.1 Press Release issued by Merck/Schering-Plough Pharmaceuticals on July 23, 2004 titled "FDA Approves VYTORIN(TM) (ezetimibe/simvastatin), the First and Only Product to Deliver Powerful LDL Cholesterol Reduction Through Dual Inhibition of the Two Sources of Cholesterol in One Tablet"

3